Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

The Safety, Tolerability And Metabolism Of GSK221149A, In Pregnant Women (30-36 Weeks), In Pre-Term Labor

ClinicalTrials.gov ID: NCT00404768

Public ClinicalTrials.gov record NCT00404768. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 21, 2026, 10:56 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Double-blind, Placebo-controlled, Dose Ranging Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK221149A Administered Intravenously and to Investigate the Pharmacokinetics of GSK221149A Administered Orally to Healthy, Pregnant Females With Uncomplicated Pre-term Labor Between 300/7 and 356/7 Weeks' Gestation

Study identification

NCT ID
NCT00404768
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
GlaxoSmithKline
Industry
Enrollment
93 participants

Conditions and interventions

Interventions

  • GSK221149A Drug
  • Placebo Drug

Drug

Eligibility (public fields only)

Age range
18 Years to 45 Years
Sex
Female
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Oct 11, 2007
Primary completion
Jul 6, 2011
Completion
Jul 6, 2011
Last update posted
Jan 15, 2018

2007 – 2011

United States locations

U.S. sites
32
U.S. states
19
U.S. cities
29
Facility City State ZIP Site status
GSK Investigational Site Mobile Alabama 36604
GSK Investigational Site Phoenix Arizona 85008
GSK Investigational Site Phoenix Arizona 85013
GSK Investigational Site Tucson Arizona 85712
GSK Investigational Site Jonesboro Arkansas 72401
GSK Investigational Site Colton California 92324
GSK Investigational Site Loma Linda California 92350
GSK Investigational Site Los Angeles California 90033
GSK Investigational Site Newark Delaware 19718
GSK Investigational Site Idaho Falls Idaho 83404
GSK Investigational Site Kansas City Kansas 66160
GSK Investigational Site Minneapolis Minnesota 55454
GSK Investigational Site St Louis Missouri 63023
GSK Investigational Site Newark New Jersey 07101-1709
GSK Investigational Site New York New York 10032
GSK Investigational Site Chapel Hill North Carolina 27514
GSK Investigational Site Southern Pines North Carolina 28388
GSK Investigational Site Winston-Salem North Carolina 27103
GSK Investigational Site Cincinnati Ohio 45267
GSK Investigational Site Philadelphia Pennsylvania 19102
GSK Investigational Site Philadelphia Pennsylvania 19140
GSK Investigational Site Charleston South Carolina 29425
GSK Investigational Site Columbia South Carolina 29201
GSK Investigational Site Chattanooga Tennessee 37403
GSK Investigational Site Knoxville Tennessee 37920-1511
GSK Investigational Site Memphis Tennessee 38119
GSK Investigational Site Galveston Texas 77555-0587
GSK Investigational Site Houston Texas 77030
GSK Investigational Site Houston Texas 77054
GSK Investigational Site Salt Lake City Utah 84124
GSK Investigational Site West Jordan Utah 84088
GSK Investigational Site Norfolk Virginia 23507-1914

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 25 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00404768, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jan 15, 2018 · Synced Jul 21, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00404768 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →